~~<i id='5C3C985840'><strike id='5C3C985840'><tt id='5C3C985840'><pre id='5C3C985840'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：explore 2025-09-27 22:18:22 - browse：72817

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： With Wegovy coverage, Medicare patients may face high costs

leisure time

knowledge

leisure time

hotspot

leisure time

STAT'sLevFacher(left)spokewiththreeaddictionexperts—(fromleft)BraunzCourtney,KeithHumphreys,andAyesh

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Data integrity in scientific journals requires "effort" by publishers, institutions

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Erich Jarvis studies song birds to learn about human stuttering

Addiction experts warn against a second 'war on drugs'

U.K. officials, researchers try to ease path for bespoke genetic treatments

leisure time

fashion

leisure time

Bright Health sells Medicare Advantage business to Molina

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Heart attack and stroke risk calculators need revising

Helping hospitals and community health centers plan for resilience

Bright Health sells Medicare Advantage business to Molina

U.K. officials, researchers try to ease path for bespoke genetic treatments

Jerome Adams on the need for new antivirals for Covid

U.K. officials, researchers try to ease path for bespoke genetic treatments

Cancer drug shortages should be causing more outrage

Cytokinetics CEO stresses company can launch heart drug on its own

knowledge

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Asbestos ban is immediate, but health effects will linger for decades

Case highlights the risks of experimental stem cell therapy

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Data integrity in scientific journals requires "effort" by publishers, institutions

NVIDIA and Google execs on the future of AI and drug discovery

leisure time

hotspot

leisure time

leisure time